A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma


Disclosures: Funding: Celgene Corporation This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672).

Contributions: MAF designed the study, analyzed the data, provided clinical care to patients, and wrote the paper; PS and DC analyzed data and wrote the paper; YO, LEF, NF, LN, YER, FS, YN, IFK and RTK provided clinical care to patients and coauthored the paper; LF wrote the statistical design of the study, analyzed data and wrote the paper; ETW, CER and MDS collected the data and coauthored the paper.